Edgewise Gets EU Orphan Drug Status for Muscular Dystrophy Drug
Seeking AlphaApr 23 10:29 ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersPaxMedica (NASDAQ:PXMD) stock moved upwards by 104.2% to $0.84 during Friday's pre-market session. The market value of their outstanding shares is at $6.2 million. Allarity Therapeutics (NASDAQ
BenzingaApr 12 08:09 ET
Insiders Buying GameStop And 2 Other Stocks
Although U.S. stocks closed mixed on Tuesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the sto
BenzingaApr 10 08:11 ET
PepGen to Participate in Upcoming Investor Conferences
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of
GlobeNewswireMar 13 16:05 ET
Express News | PepGen Receives U.S. FDA Orphan Drug And Rare Pediatric Disease Designations For PGN-EDO51 For The Treatment Of Duchenne Muscular Dystrophy
Moomoo 24/7Mar 13 07:01 ET
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
PepGen Inc. (Nasdaq: PEPG) today announced that the U.S. Food and Drug Administration (FDA) granted both orphan drug and rare pediatric disease designations for PGN-EDO51, an investigational therapeutic for Duchenne muscular dystrophy (DMD) patients whose mutations are amenable to an exon 51 skipping approach. PepGen is evaluating PGN-EDO51 for the treatment of DMD in the ongoing CONNECT1 Phase 2 trial, and expects to begin enrolling patients in the CONNECT2 Phase 2 trial later this year.
GlobeNewswireMar 13 07:00 ET
Stifel Nicolaus Reaffirms Their Buy Rating on PepGen Inc. (PEPG)
TipRanksMar 11 22:15 ET
Earnings Call Summary | PepGen(PEPG.US) Q4 2023 Earnings Conference
The following is a summary of the PepGen, Inc. (PEPG) Q4 2023 Earnings Call Transcript:Financial Performance:PepGen finished 2023 with $110.4 million in cash and cash equivalents, a significant decrea
moomoo AIMar 7 18:41 ET · Conference Call
Berkshire Hills Bancorp, Inc. Declares $0.18 Dividend
Seeking AlphaMar 7 17:20 ET
PepGen, Inc. (PEPG) Q4 2023 Earnings Call Transcript
PepGen, Inc. (PEPG) Q4 2023 Earnings Call Transcript
Earnings Call TranscriptsMar 7 17:10 ET
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersPsyence Biomedical (NASDAQ:PBM) stock moved upwards by 35.3% to $1.38 during Thursday's regular session. The market value of their outstanding shares is at $18.4 million. ZyVersa Therapeutics (
BenzingaMar 7 12:31 ET
Express News | PepGen Shares Are Trading Lower After the Company Reported Q4 EPS Results. Also, Wedbush Maintained an Outperform Rating on the Stock and Lowered Its Price Target From $21 to $20
Moomoo 24/7Mar 7 10:59 ET
Express News | PepGen Reported March 6 Q4 2023 GAAP EPS $(0.810) Beats $(1.010) Estimate
Moomoo 24/7Mar 7 10:55 ET
Analysts Are Bullish on Top Healthcare Stocks: Generation Bio (GBIO), PepGen Inc. (PEPG)
TipRanksMar 7 08:30 ET
PepGen Is Maintained at Outperform by Wedbush
PepGen Is Maintained at Outperform by Wedbush
Dow JonesMar 7 08:24 ET
PepGen Price Target Cut to $20.00/Share From $21.00 by Wedbush
PepGen Price Target Cut to $20.00/Share From $21.00 by Wedbush
Dow JonesMar 7 08:24 ET
PepGen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/07/2024 29.79% Wedbush $21 → $20 Maintains Outperform 01/30/2024 36.28% Wedbush → $21 Reiterates Outper
BenzingaMar 7 08:12 ET
Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG), ITeos Therapeutics (ITOS) and Rezolute (RZLT)
TipRanksMar 7 06:30 ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: PepGen Inc. (PEPG), BridgeBio Pharma (BBIO) and Amedisys (AMED)
TipRanksMar 6 23:20 ET
PepGen 4Q Loss $19.5M >PEPG
PepGen 4Q Loss $19.5M >PEPG
Dow JonesMar 6 16:07 ET
No Data
No Data